Curebase has raised $40m in a Series B financing round led by Industry Ventures to advance the development of its end-to-end clinical trial execution model.

The funding round also saw participation from new institutional investors Acrew Capital, Positive Sum and World Innovation Lab and current investors GGV Capital, Xfund and Bold Capital. 

GGV Capital had led the Series A funding. 

As part of the financing round, Curebase also received a strategic investment from Gilead Sciences to expand their collaboration to implement decentralised clinical trial (DCT) and hybrid expertise in interventional studies.

Furthermore, Gaingels, an investment syndicate focusing on startups which build varied and inclusive teams, took part in the funding. 

The company also intends to use the proceeds to develop virtual and hybrid site expertise and complete eClinical software platform to conduct patient-centric clinical trials. 

In addition, the funding will expand range of its expertise beyond the virtual experience through intricate site and community healthcare interfaces, a stronger expertise for interventional drug sponsors and international trials and a broader range of clinical software and services.

Curebase founder and CEO Tom Lemberg said: “We are pleased that investors are recognising that Curebase is more than a software platform. 

“We are an end-to-end clinical trial company with global capabilities and an extensive site network of virtual and hybrid site staff that provides everything needed to successfully execute a better clinical trial.”

Established in 2017, the company is an expert in DCTs and patient-centric clinical trial software and has raised $59m till date.